title: Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.
abstract: BACKGROUND
  This multicentre phase II open-label study evaluated safety and antitumour activity of oxaliplatin in cisplatin or carboplatin (cis/carboplatin) +/- taxane-pretreated advanced ovarian cancer (AOC) patients.
  
  
  METHODS
  Forty-eight patients received oxaliplatin 130 mg/M2 intravenously every 3 weeks, 94% having a performance status (PS) 0-1. All were pretreated with cis/carboplatin and 21 (44%) with paclitaxel. The median number of involved organs was two, 18 (38%) had liver metastasis, 23 (48%) were platinum-resistant and 14 (29%) were taxane-resistant. Forty-two patients were evaluable for a response, 18 (43%) were platinum-resistant and 11 (26%) were taxane-resistant.
  
  
  RESULTS
  A total of 253 cycles was administered (median: 5.5/patient). Median cumulative oxaliplatin dose was 666 mg/m2. National Cancer Institute-Common Toxicity Criteria toxicity analysis showed that seven patients (15%) had grade 3/4 thrombocytopenia, two patients (4%) had grade 3 neutropenia, and one patient had grade 3 anaemia. Eleven patients (23%) experienced grade 3 neurosensory toxicity. Of the 29 patients with peripheral neuropathy at the end of treatment, 55% had recovered or improved 1 month later. Eleven objective responses (two complete) were obtained in the 42 evaluable patients [ORR 26%, 95% confidence interval (CI) 14% to 42%], with 10/24 (42%, 95% CI 22% to 63%) in platinum-sensitive, and 1 of 18 (5.6%, 95% CI 0% to 27%) in platinum-resistant patients. Median response duration was 9.2 months (95% CI 6.6% to 11.8%), and median progression-free and overall survival in all treated patients were 4.3 months (95% CI 3.0% to 5.7%) and 15.0 months (95% CI 11.1% to 18.8%), respectively.
  
  
  CONCLUSIONS
  Oxaliplatin has a good safety profile and is active in cis/carboplatin +/- paclitaxel-pretreated AOC patients.
authors.affiliation: Institut Curie, Paris, France. veronique.dieras@curie.net
authors.forename: V
authors.initials: V
authors.lastname: Dieras
authors.forename: P
authors.initials: P
authors.lastname: Bougnoux
authors.forename: T
authors.initials: T
authors.lastname: Petit
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: C
authors.initials: C
authors.lastname: Borel
authors.forename: F
authors.initials: F
authors.lastname: Husseini
authors.forename: A
authors.initials: A
authors.lastname: Goupil
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: J L
authors.initials: JL
authors.lastname: Misset
authors.forename: M A
authors.initials: MA
authors.lastname: Bensmaïne
authors.forename: I
authors.initials: I
authors.lastname: Tabah-Fisch
authors.forename: P
authors.initials: P
authors.lastname: Pouillart
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000032:analysis; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage
chemical_list: D018394:CA-125 Antigen; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin